Malaria is one of the most dreadful diseases on the planet earth and nearly half of the world population is at a risk of this infection. Because of the advancement in medication and therapeutics, malaria related death toll has seen a 48% drop from estimated 839,000 in 2000 to 438,000 in 2015 [1, 2] . Most of this life-threatening disease causality is in tropical climate of Sub-Saharan Africa (90%) and South-East Asia (7.5%) and because of the weak infrastructure in some countries the challenge to fight this disease has been an uphill battle. Multiplied with the parasitic, intra-cellular life cycle of the Plasmodium species (P. falciparum, P. vivax, P. malariae and P. ovale) makes it even harder to develop vaccine. Current antimalarial medications such as artemisinin, chloroquine, sulfonamides, pyrimethamine, etc. are failing in treatment of malaria because of increasing drug-resistance by Plasmodium species.
This drug resistance has been recurring problem to treat various parasitic diseases (caused by Trypanosoma brucei, Toxoplasma gondii, Leishmania species) and bacterial infectious diseases (caused by Staphylococcus aureus, Group A Streptococcus, Clostridium difficile, Neisseria gonorrhoeae) as well. The only solution to these arduous problems is through development of new druggable targets. The whole genome sequence of P. falciparum has provided information about the vital metabolic pathways used for survival and resistance; and how these can be targeted to develop new generation of antimalarial [3] . Some of the most relevant biological target in Plasmodium that has been identified and localized, such as 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway, type II fatty acid synthesis, iron sulfur cluster assembly, fragmented heme synthesis [3] , and complete absence in the mammalian host, makes them an appealing target for drug discovery. All these pathways have been localized into apicoplast of Plasmodium, an essential organelle that is homologous to plants and algae plastids [4, 5] . All the proteins involved in the above mentioned pathways are nuclear encoded and transported to apicoplast through a two steps process with the help of signal and transit peptide [4] , making this organelle indispensable for Plasmodium survival. Some bacteria also use this mevalonate-independent pathway for isoprenoid synthesis, thus making this pathway an attractive target for antibiotics development.
Various proteins in MEP pathway have recently been targeted for antimicrobial drug development. 1-Deoxy-D-xylulose-5-Phosphate Synthase (DXS) the rate-limiting enzyme of MEP pathway, which catalyze the first step in MEP pathway through biosynthesis of 1-deoxy-D-xylulose-5-phosphate (DXP), by condensation of pyruvate and glyceraldehyde 3-phosphate (GAP) is example of an appealing target [6] . DXS belongs to thiamine diphosphate (TDP) dependent enzyme and share a high homology with mammalian pyruvate dehydrogenase, and transketolase [7] . But DXS display some distinct structural [7] and mechanistic features [8, 9] which sets it apart from other TDP-dependent enzymes, making this as an attractive target for drug development.
Some of the very first study reported was on structure-activity target development against DXS of Mycobacterium tuberculosis, using known transketolase inhibitor [10] . This study reported an inhibitor of M. tuberculosis DXS with and IC 50 of 10.6 μM. After this report several other findings were also published, where acetylphosphonate and hydroxybenzaldoximes derivatives, mimicking the active-site pocket of DXS were synthesized and shown a promising inhibition of E. coli DXS at IC 50 value for some derivatives just below 10 μM [11, 12] . Antimicrobial N-(2-chlorobenzyl)-substituted hydroxamate (hydrolysis product of ketoclomazone) shows inhibition for Haemophilus influenza DXS, even at lower IC 50 value of 1.0 μM [13] . Recent report on the development of DXS from P. falciparum and P. vivax using an overexpression system in E. coli, has open an attractive target for new generation of antimalarial discovery [14, 15] as well. DXS from both the Plasmodium species are inhibited by β-Fluoropyruvate (F-Pyr) and methylacetylphosphonate (MAP), though a competitive inhibition with respect to pyruvate and noncompetitive against GAP [15] . A homology model of P. vivax and other Plasmodium species (P. falciparum, P. berghei) DXS has also been reported recently, and has been validated for virtual screening of target using NCI diversity set [16] . All the inhibitors developed so far against bacterial DXS have still to be tested against Plasmodium DXS to check their efficacy and then come up with a moiety to design a better drug candidate.
Current challenges with the development of selective and new generation of antimalarial have been hindered by the lack of new targets. Since DXS is involved in the first rate-limiting step in the MEP pathway and also shows feedback inhibition by the end product of MEP pathway [9] , thereby making DXS a convincing drug development target in the field of malaria therapeutics.
